Zobrazeno 1 - 10
of 14
pro vyhledávání: '"BA, Bile acids"'
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 9, Iss 2, Pp 220-236 (2019)
Acta Pharmaceutica Sinica B, Vol 9, Iss 2, Pp 220-236 (2019)
Obesity is increasing in an alarming rate worldwide, which causes higher risks of some diseases, such as type 2 diabetes, cardiovascular diseases, and cancer. Current therapeutic approaches, either pancreatic lipase inhibitors or appetite suppressors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee24ee4e685885a371ae80f1d618f98
https://doi.org/10.1016/j.apsb.2018.09.007
https://doi.org/10.1016/j.apsb.2018.09.007
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology
Cellular and Molecular Gastroenterology and Hepatology, Vol 8, Iss 2, Pp 235-246 (2019)
Cellular and Molecular Gastroenterology and Hepatology, Vol 8, Iss 2, Pp 235-246 (2019)
Bariatric surgery is the most effective and durable treatment for morbid obesity, with an unexplained yet beneficial side effect of restoring insulin sensitivity and improving glycemia, often before weight loss is observed. Among the many contributin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36ff49eff0989dc2bc68d2a48e2e1b8
https://doi.org/10.1016/j.jcmgh.2019.04.014
https://doi.org/10.1016/j.jcmgh.2019.04.014
Autor:
Spatz, Madeleine, Ciocan, Dragos, Merlen, Gregory, Rainteau, Dominique, Humbert, Lydie, Gomes-Rochette, Neuza, Hugot, Cindy, Trainel, Nicolas, Mercier-Nomé, Françoise, Domenichini, Séverine, Puchois, Virginie, Wrzosek, Laura, Ferrere, Gladys, Tordjmann, Thierry, Perlemuter, Gabriel, Cassard, Anne-Marie
Publikováno v:
JHEP Reports, Vol 3, Iss 2, Pp 100230-(2021)
JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100230. ⟨10.1016/j.jhepr.2021.100230⟩
JHEP Reports
JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100230. ⟨10.1016/j.jhepr.2021.100230⟩
JHEP Reports
Background & Aims Bile-acid metabolism and the intestinal microbiota are impaired in alcohol-related liver disease. Activation of the bile-acid receptor TGR5 (or GPBAR1) controls both biliary homeostasis and inflammatory processes. We examined the ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ae520b76500b6b211e8c427c2e781d78
http://www.sciencedirect.com/science/article/pii/S2589555921000069
http://www.sciencedirect.com/science/article/pii/S2589555921000069
Autor:
Grzych, Guillaume, Chavez-Talavera, Oscar, Descat, Amandine, Thuillier, Dorothee, Verrijken, An, Kouach, Mostafa, Legry, Vanessa, Verkindt, Helene, Raverdy, Violeta, Legendre, Benjamin, Caiazzo, Robert, Van Gaal, Luc, Goossens, Jean-Francois, Paumelle, Rejane, Francque, Sven, Pattou, Francois, Haas, Joel T., Tailleux, Anne, Staels, Bart
Publikováno v:
JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, 2021, 3 (2), pp.100222. ⟨10.1016/j.jhepr.2020.100222⟩
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100222. ⟨10.1016/j.jhepr.2020.100222⟩
JHEP Reports
JHEP Reports, Vol 3, Iss 2, Pp 100222-(2021)
JHEP Reports Innovation in Hepatology, 2021, 3 (2), pp.100222. ⟨10.1016/j.jhepr.2020.100222⟩
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100222. ⟨10.1016/j.jhepr.2020.100222⟩
JHEP Reports
JHEP Reports, Vol 3, Iss 2, Pp 100222-(2021)
Background & Aims Plasma bile acids (BAs) have been extensively studied as pathophysiological actors in non-alcoholic steatohepatitis (NASH). However, results from clinical studies are often complicated by the association of NASH with type 2 diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::74e69ecb4a62b415846d1ee012802a9c
https://www.hal.inserm.fr/inserm-03173334/document
https://www.hal.inserm.fr/inserm-03173334/document
Autor:
Malte P. Suppli, Cristina Alonso, Bruno Sangro, Ekaterina Zhuravleva, Rocio I.R. Macias, Filip K. Knop, Emma Eizaguirre, Manuel Romero-Gómez, Jesus M. Banales, Alvaro Santos-Laso, Raul Jimenez-Agüero, Jesper B. Andersen, Marco Arrese Jimenez, Monika Lewinska, Stine Karlsen Oversoe, Flair José Carrilho, Gerda Elisabeth Villadsen, María Jesús Pareja, Claudia Pms de Oliveira, Thomas Decaens, Enara Arretxe
Publikováno v:
EBioMedicine, Vol 73, Iss, Pp 103661-(2021)
Lewinska, M, Santos-Laso, A, Arretxe, E, Alonso, C, Zhuravleva, E, Jimenez-Agüero, R, Eizaguirre, E, Pareja, M J, Romero-Gómez, M, Arrese, M, Suppli, M P, Knop, F K, Oversoe, S K, Villadsen, G E, Decaens, T, Carrilho, F J, de Oliveira, C P, Sangro, B, Macias, R I R, Banales, J M & Andersen, J B 2021, ' The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma ', EBioMedicine, vol. 73, pp. 103661 . https://doi.org/10.1016/j.ebiom.2021.103661
Addi. Archivo Digital para la Docencia y la Investigación
instname
EBioMedicine
Digital.CSIC. Repositorio Institucional del CSIC
Lewinska, M, Santos-Laso, A, Arretxe, E, Alonso, C, Zhuravleva, E, Jimenez-Agüero, R, Eizaguirre, E, Pareja, M J, Romero-Gómez, M, Arrese, M, Suppli, M P, Knop, F K, Oversoe, S K, Villadsen, G E, Decaens, T, Carrilho, F J, de Oliveira, C P, Sangro, B, Macias, R I R, Banales, J M & Andersen, J B 2021, ' The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma ', EBioMedicine, vol. 73, pp. 103661 . https://doi.org/10.1016/j.ebiom.2021.103661
Addi. Archivo Digital para la Docencia y la Investigación
instname
EBioMedicine
Digital.CSIC. Repositorio Institucional del CSIC
[Background] Non-alcoholic fatty liver disease (NAFLD) is affecting more people globally. Indeed, NAFLD is a spectrum of metabolic dysfunctions that can progress to hepatocellular carcinoma (NAFLD-HCC). This development can occur in a non-cirrhotic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4da069c4db0add797224a1fd8ecbf5f1
https://doi.org/10.2139/ssrn.3894905
https://doi.org/10.2139/ssrn.3894905
Autor:
Luca Miele, Erika Paolini, Miriam Longo, Valentina D'Oria, Annalisa Crudele, Marco Maggioni, Luca Valenti, Marica Meroni, Paola Dongiovanni, Emanuele Bellacchio, Anna Alisi, Nadia Panera, Anna Ludovica Fracanzani
Publikováno v:
EBioMedicine
EBioMedicine, Vol 65, Iss, Pp 103249-(2021)
EBioMedicine, Vol 65, Iss, Pp 103249-(2021)
Background The rs17618244 G>A β-Klotho (KLB) variant has been associated with increased risk of ballooning and inflammation in pediatric patients with metabolic associated fatty liver disease (MAFLD), by reducing KLB expression. In hepatocytes, KLB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b73168cc030189c281702ac035f66d
https://doi.org/10.1016/j.ebiom.2021.103249
https://doi.org/10.1016/j.ebiom.2021.103249
Autor:
Jasmohan S. Bajaj, Jason M. Ridlon
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 5, Iss 2, Pp 99-105 (2015)
Acta Pharmaceutica Sinica B, Vol 5, Iss 2, Pp 99-105 (2015)
The human body is now viewed as a complex ecosystem that on a cellular and gene level is mainly prokaryotic. The mammalian liver synthesizes and secretes hydrophilic primary bile acids, some of which enter the colon during the enterohepatic circulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39a47a3373a81cd635cb86b4c8dbf2d
Publikováno v:
Metabolism Open, Vol 3, Iss, Pp-(2019)
Metabolism Open
Metabolism Open
Background Cystic fibrosis lung disease is characterized by chronic bacterial infections in the setting of mucus abnormalities. Patients experience periodic exacerbations that manifest with increased respiratory symptoms that require intensification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89fed7b6362cae0a000083f3c25c4da
https://doi.org/10.1016/j.metop.2019.100010
https://doi.org/10.1016/j.metop.2019.100010
Autor:
Grzych G; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Chávez-Talavera O; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Descat A; Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France., Thuillier D; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Verrijken A; Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk/Antwerp, Belgium.; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, 2650 Edegem/Antwerp, Belgium., Kouach M; Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France., Legry V; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Verkindt H; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Raverdy V; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Legendre B; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Caiazzo R; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Van Gaal L; Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk/Antwerp, Belgium.; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, 2650 Edegem/Antwerp, Belgium., Goossens JF; Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France., Paumelle R; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Francque S; Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk/Antwerp, Belgium.; Department of Gastroenterology and Hepatology, Antwerp University Hospital, 2650, Edegem, Antwerp, Belgium., Pattou F; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Haas JT; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Tailleux A; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Staels B; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France.
Publikováno v:
JHEP reports : innovation in hepatology [JHEP Rep] 2020 Dec 16; Vol. 3 (2), pp. 100222. Date of Electronic Publication: 2020 Dec 16 (Print Publication: 2021).
Autor:
Muhlebach MS; Dept. Pediatrics, Division Pulmonary Medicine, University of North Carolina at Chapel Hill, 450 MacNider, 330 S. Columbia Road, Chapel Hill, NC, 27599-7217, USA.; Marsico Lung Institute, Chapel Hill, NC, USA., Sha W; Bioinformatics Services Division, Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, 150 Research Campus Dr, Kannapolis, NC 28081, NC, USA., MacIntosh B; Metabolic and Nutrition Research Core, UNC Healthcare, Nutrition and Food Services Department, 102 Mason Farm Rd, CB#7777, Chapel Hill, NC, USA., Kelley TJ; Departments of Pediatrics/Pharmacology, Case Western Reserve University, 833 BRB, 10900, Euclid Ave, Cleveland, OH, USA., Muenzer J; Dept. Pediatrics, Division Metabolism and Genetics, University of North Carolina at Chapel Hill, USA.
Publikováno v:
Metabolism open [Metabol Open] 2019 Jun 08; Vol. 3, pp. 100010. Date of Electronic Publication: 2019 Jun 08 (Print Publication: 2019).